Voices
Stephen V Liu: Comparable OS With Subcutaneous vs Intravenous Atezolizumab in NSCLC
Stephen Liu/X

Stephen V Liu: Comparable OS With Subcutaneous vs Intravenous Atezolizumab in NSCLC

Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on shared a post on X:

“IMscin001 and IMscin002 compare subcutaneous atezolizumab vs intravenous. With longer follow up, comparable OS in NSCLC (HR 1.00) with no new or unexpected safety signals and comparable immunogenicity.”

 

Title: Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies

Authors: Mauricio Burotto, Zanete Zvirbule, Renzo Alvarez, Busyamas Chewaskulyong, Enriqueta Felip, Margarita Majem, Ernesto Korbenfeld, Jaroslaw Kolb-Sielecki, Dolores Isla, Teresa Barata, Alberto Bustillos, Luis A. Herraez-Baranda, Nadia Tosti, Fiona Young, James Zanghi, Federico Cappuzzo

Read the Full Article.

Stephen V Liu: Comparable OS With Subcutaneous vs Intravenous Atezolizumab in NSCLC

Second-Event Endpoints After Anti–PD-(L)1 Therapy: Are We Measuring Immunotherapy Benefit the Right Way?
Stephen V Liu: Comparable OS With Subcutaneous vs Intravenous Atezolizumab in NSCLC

Alberto Bustillos Busyamas Chewaskulyong cancer Dolores Isla Enriqueta Felip Ernesto Korbenfeld Federico Cappuzzo Fiona Young James Zanghi Jaroslaw Kolb-Sielecki Luis A. Herraez-Baranda Lung cancer Margarita Majem Mauricio Burotto Nadia Tosti NSCLC OncoDaily Oncology Renzo Alvarez Stephen V Liu Teresa Barata Zanete Zvirbule